Determinants of long-term survival in a population-based cohort study of patients with head and neck cancer from Scotland.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
06 2019
Historique:
received: 28 03 2018
revised: 15 11 2018
accepted: 19 12 2018
pubmed: 9 1 2019
medline: 12 11 2020
entrez: 9 1 2019
Statut: ppublish

Résumé

We investigated long-term survival from head and neck cancer (HNC) using different survival approaches. Patients were followed-up from the Scottish Audit of Head and Neck Cancer. Overall survival and disease-specific survival were calculated using the Kaplan-Meier method. Net survival was calculated by the Pohar-Perme method. Mutually adjusted Cox proportional hazards models were used to determine the predictors of survival. A total of 1820 patients were included in the analyses. Overall survival at 12 years was 26.3% (24.3%, 28.3%). Disease-specific survival at 12 years was 56.9% (54.3%, 59.4%). Net survival at 12 years was 41.4% (37.6%, 45.1%). Determinants associated with long-term survival included age, stage, treatment modality, WHO performance status, alcohol consumption, smoking behavior, and anatomical site. We recommend that net survival is used for long-term outcomes for HNC patients-it disentangles other causes of death, which are overestimated in overall survival and underestimated in disease-specific survival.

Sections du résumé

BACKGROUND
We investigated long-term survival from head and neck cancer (HNC) using different survival approaches.
METHODS
Patients were followed-up from the Scottish Audit of Head and Neck Cancer. Overall survival and disease-specific survival were calculated using the Kaplan-Meier method. Net survival was calculated by the Pohar-Perme method. Mutually adjusted Cox proportional hazards models were used to determine the predictors of survival.
RESULTS
A total of 1820 patients were included in the analyses. Overall survival at 12 years was 26.3% (24.3%, 28.3%). Disease-specific survival at 12 years was 56.9% (54.3%, 59.4%). Net survival at 12 years was 41.4% (37.6%, 45.1%).
CONCLUSION
Determinants associated with long-term survival included age, stage, treatment modality, WHO performance status, alcohol consumption, smoking behavior, and anatomical site. We recommend that net survival is used for long-term outcomes for HNC patients-it disentangles other causes of death, which are overestimated in overall survival and underestimated in disease-specific survival.

Identifiants

pubmed: 30620423
doi: 10.1002/hed.25630
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1908-1917

Subventions

Organisme : British Association of Head and Neck Oncologists
Pays : International
Organisme : Clinical Resource and Audit Group, Scottish Executive Health Department
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Kate Ingarfield (K)

School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom.

Alex D McMahon (AD)

School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom.

Catriona M Douglas (CM)

Department of Otolaryngology - Head and Neck Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.

Shirley-Anne Savage (SA)

Emergency Care and Medicine Directorate, Victoria Hospital, United Kingdom.

David I Conway (DI)

School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom.

Kenneth MacKenzie (K)

Department of Otolaryngology - Head and Neck Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH